Advertisement

Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review

  • Hyeon Cheun
  • Miso Kim
  • Hajeong Lee
  • Kook-Hwan Oh
  • Bhumsuk Keam
SHORT REPORT

Summary

Despite the lack of safety and efficacy data regarding immune checkpoint inhibitors (ICIs) for renal dysfunction, they have been approved to treat even in the patients with end-stage renal disease (ESRD). We report our experience with ICI administration to three ESRD patients undergoing hemodialysis. One of the patients had a partial response for several months; however, the other patients had a stable disease while undergoing dialysis. The toxicity was tolerable; however, one patient developed grade 2 pneumonitis. A literature review of other rarely reported cases of hemodialysis revealed that 10 out of 13 patients had a partial response or complete response; in addition, grade 3 or grade 4 immune-related adverse events occurred in 3 patients. ESRD combined with dialysis may not be a contraindication for the use of ICIs. ICIs can be beneficial to ESRD patients undergoing dialysis. However, caution is needed regarding immune-related adverse events. Further prospective studies involving pharmacokinetic analyses are necessary to obtain reliable safety and efficacy data.

Keywords

Immune checkpoint inhibitor End-stage renal disease Dialysis 

Notes

Funding

This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declared that they have no conflict of interest.

Research involving human participants

This work was performed in humans with approval from the Institutional Review Board.

Informed consent

The Institutional Review Board granted a waiver for this retrospective study.

References

  1. 1.
    Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813.  https://doi.org/10.1056/NEJMoa1510665 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF (2017) Pembrolizumab as second-line therapy for advanced Urothelial carcinoma. N Engl J Med 376:1015–1026.  https://doi.org/10.1056/NEJMoa1613683 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med 375:1823–1833.  https://doi.org/10.1056/NEJMoa1606774 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL (2017) Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and friends of Cancer research joint research statement. J Clin Oncol Off J Am Soc Clin Oncol 35:3737–3744.  https://doi.org/10.1200/JCO.2017.73.7916 CrossRefGoogle Scholar
  5. 5.
    Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS (2018) Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. Thorac Cancer 9:736–744.  https://doi.org/10.1111/1759-7714.12641 CrossRefPubMedGoogle Scholar
  6. 6.
    Donia M, Kimper-Karl ML, Høyer KL, Bastholt L, Schmidt H, Svane IM (1990) (2017) the majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. Eur J Cancer Oxf Engl 74:89–95.  https://doi.org/10.1016/j.ejca.2016.12.017 CrossRefGoogle Scholar
  7. 7.
    Janus N, Launay-Vacher V (2015) Anticancer drugs in end-stage kidney disease patients. Semin Dial 28:413–416.  https://doi.org/10.1111/sdi.12371 CrossRefPubMedGoogle Scholar
  8. 8.
    Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143–e152.  https://doi.org/10.1016/S1470-2045(17)30074-8 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B (2008) Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol CJASN 3:1526–1533.  https://doi.org/10.2215/CJN.00950208 CrossRefPubMedGoogle Scholar
  10. 10.
    Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD (2017) Pneumonitis in patients treated with anti-programmed Death-1/programmed death ligand 1 therapy. J Clin Oncol Off J Am Soc Clin Oncol 35:709–717.  https://doi.org/10.1200/JCO.2016.68.2005 CrossRefGoogle Scholar
  11. 11.
    Opdivo (nivolumab) injection label by FDA (available at https://www.accessdata.fda.gov)
  12. 12.
    Yervoy (ipilimumab) injection label by FDA (available at https://www.accessdata.fda.gov)
  13. 13.
    Keytruda (pembrolizumab) injection label by FDA (available at https://www.accessdata.fda.gov)
  14. 14.
    Tecentriq (atezolizumab) injection label by FDA (available at https://www.accessdata.fda.gov)
  15. 15.
    2013-Dialysis-Drugs.pdf (available at https://homedialyzorsunited.org)
  16. 16.
    Nakauchi H, Okumura K, Tango T (1981) Immunoglobulin levels in patients on long-term hemodialysis. N Engl J Med 305:172–173.  https://doi.org/10.1056/NEJM198107163050320 CrossRefPubMedGoogle Scholar
  17. 17.
    Jillella AP, Dainer PM, Kallab AM, Ustun C (2002) Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. Am J Hematol 71:219–222.  https://doi.org/10.1002/ajh.10213 CrossRefPubMedGoogle Scholar
  18. 18.
    Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A (2016) Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol Off J Eur Soc Med Oncol 27:214–224.  https://doi.org/10.1093/annonc/mdv550 CrossRefGoogle Scholar
  19. 19.
    Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE III, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström AC, Abidoye OO, Fine GD, Bajorin DF (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet Lond Engl 389:67–76.  https://doi.org/10.1016/S0140-6736(16)32455-2 CrossRefGoogle Scholar
  20. 20.
    Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y (2017) Model-based population pharmacokinetic analysis of Nivolumab in patients with solid tumors. CPT Pharmacomet Syst Pharmacol 6:58–66.  https://doi.org/10.1002/psp4.12143 CrossRefGoogle Scholar
  21. 21.
    Cavalcante L, Amin A, Lutzky J (2015) Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease. Cancer Manag Res 7:47–50.  https://doi.org/10.2147/CMAR.S73389 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Chang R, Shirai K (2016) Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ Case Rep 2016: pii: bcr2016216426. doi:  https://doi.org/10.1136/bcr-2016-216426
  23. 23.
    Carlo MI, Feldman DR (2016) Response to Nivolumab in a patient with metastatic clear cell renal cell carcinoma and end-stage renal disease on Dialysis. Eur Urol 70:1082–1083.  https://doi.org/10.1016/j.eururo.2016.05.040 CrossRefPubMedGoogle Scholar
  24. 24.
    Tabei T, Natsume I, Kobayashi K (2017) Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment. Int J Urol Off J Jpn Urol Assoc 24:708–710.  https://doi.org/10.1111/iju.13420 CrossRefGoogle Scholar
  25. 25.
    Ansari J, Ali M, Farrag A, Ali AM, Alhamad A (2018) Efficacy of Nivolumab in a patient with metastatic renal cell carcinoma and end-stage renal disease on Dialysis: case report and literature review. Case Rep Immunol 2018:1623957–1623954.  https://doi.org/10.1155/2018/1623957 CrossRefGoogle Scholar
  26. 26.
    Park S, Daniels GA (2017) Anti-PD-1 therapy in patients with end-stage renal disease on dialysis: a single-center case series. J Clin Oncol 35:e14553–e14553.  https://doi.org/10.1200/JCO.2017.35.15_suppl.e14553 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Seoul National University College of MedicineSeoulSouth Korea
  2. 2.Department of Internal MedicineSeoul National University HospitalSeoulSouth Korea
  3. 3.Cancer Research InstituteSeoul National UniversitySeoulSouth Korea

Personalised recommendations